Human Immune System Mice
- Products
- Animal Models
- Human Immune System Mice
- huHSC-NCG
huHSC-NCG
Type : CD34+ Humanized Mice
Strain Number: T037620
Background Strain: NCG [T001475]
HuHSC-NCG Mice (as known as CD34+ humanized mice) are NCG [T001475] mice engrafted with cord blood human CD34⁺ hematopoietic stem cells (CD34+ HSC). These models allow for the long-term reconstitution of a functional human hematopoietic and immune system in mouse. This makes them an essential tool in Immuno-oncology, immunology, infectious disease and autoimmune disease investigation.
Features of HuHSC-NCG
1.Functional human Immune cell subsets (T, B, NK, myeloid)
2.Minimal 20% hCD45 in peripheral blood
3.Stable engraftment and long Lifespan > 39 weeks
4.Customizable :
- huHSC-NCG-hIL15 for NK-T interaction and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) assessment
- huHSC-NCG-M for T-cell and Myeloid dependent Efficacy studies
- HLA partially matching for cells and tissue transplantation
Oncology and
Immuno-oncology
Immunology & Inflammation
Infectious Diseases
Safety Assessment
e.g CAR-T induced Cytokine Storm
Autoimmune Diseases
Fig 1: Body wight and immune profile of huHSC-NCG post 4 to 16 weeks of of CD34+ HSC engraftment.
The huHSC-NCG mouse model is generated by transplanting purified human CD34⁺ hematopoietic stem cells derived from cord blood into severely immunodeficient NCG, NCG-hIL15 or NCG-M mice. Prior to transplantation, mice are preconditioned with sublethal irradiation to clear native hematopoietic cells and improve engraftment efficiency. CD34⁺ cells are injected intravenously. Over 8–12 weeks, the mice develop a functional human immune system with multilineage reconstitution, including human T, B, NK cells, and myeloid populations.
- Hu B et al. Interferon-α potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment. Cancer Discovery, 2022. IF: 39.4
- Ma W et al. Biomimetic nanoerythrosome‐coated aptamer‐DNA tetrahedron/Maytansine conjugates: pH‐responsive and targeted cytotoxicity for HER2‐positive breast cancer. Advanced Materials, 2021. IF: 30.8
- Song H et al. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Molecular Cancer, 2022. IF: 41.4
- Zhang L et al. Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metabolism, 2021. IF: 22.4
- Liu C et al. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metabolism, 2022. IF: 22.4
Axiocell Biotech Sdn Bhd.
Suite 2-5, Level 18, Plaza Azalea 10, Persiaran Bandaraya, Seksyen 14, 40000 Shah Alam, Selangor.
© 2025 AXIOCELL BIOTECH. All rights reserved.
Developed by Infinicore – Design by LeMoon